Category: Clinical Research

Home / Clinical Research
Satish Shah, MD, our Medical Director, speaks about Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors.
Post

Satish Shah, MD, our Medical Director, speaks about Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors.

Satish Shah, MD, Medical Director, Gettysburg Cancer Center speaks about Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors.   Watch Video   Link to Article: http://www.globenewswire.com/news-release/2021/03/24/2198364/0/en/Theratechnologies-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-TH1902-for-Sortilin-Positive-Solid-Tumors.html Theratechnologies Inc., a biopharmaceutical company focusing on the discovery and commercialization of novel therapies, is pleased to report that the...

Gettysburg Cancer Center (GCC) has administered the first dose of a new, innovative cancer therapy ever given to a human being anywhere in the world
Post

Gettysburg Cancer Center (GCC) has administered the first dose of a new, innovative cancer therapy ever given to a human being anywhere in the world

This news release is an announcement that the Gettysburg Cancer Center (GCC) has administered the first dose of a new, innovative cancer therapy ever given to a human being anywhere in the world. This is a testament to the dedication and hard work of the doctors and staff of GCC to ensure that Gettysburg and...

Study of TH1902 in Patients with Advanced Solid Tumors and Expansion
Post

Study of TH1902 in Patients with Advanced Solid Tumors and Expansion

A Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients with Advanced Solid Tumors and Expansion in Patients with Triple Negative Breast Cancer, Gynecological Cancer, Colorectal cancer, and Pancreatic Cancer. Even though this study is a Phase 1 it received FDA Fast Track Approval on February 4, 2021. An excerpt from the News Release...

Trilaciclib Prior to Myelosuppressive Chemo Reduces Need for Supportive Care in Small Cell Lung Cancer
Post

Trilaciclib Prior to Myelosuppressive Chemo Reduces Need for Supportive Care in Small Cell Lung Cancer

December 9, 2020 – Hayley Virgil Renata Ferrarotto, MD, discusses trilaciclib’s unique mechanism of action in small cell lung cancer and the data that led to its FDA designation. Trilaciclib administered prior to chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC) helped to reduce chemotherapy-induced myelosuppression and limit the need for granulocyte colony-stimulating factors...

Similarities in Risk for COVID-19 and Cancer Disparities
Post

Similarities in Risk for COVID-19 and Cancer Disparities

Lisa A. Newman, Robert A. Winn and John M. Carethers DOI: 10.1158/1078-0432.CCR-20-3421 Published January 2021 Abstract Coronavirus disease 2019 (COVID-19) is a novel infectious disease that has spread worldwide. In the United States, COVID-19 disproportionately affects racial and ethnic minorities, particularly African Americans, with an observed 2-fold higher rate for hospitalization and greater than 2-fold higher rate for death as compared with White Americans....

Treatment of malignancy associated weight loss or anorexia in patients with NSCLC
Post

Treatment of malignancy associated weight loss or anorexia in patients with NSCLC

STUDY TITLE: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in adult patients with Advanced Non-Small Cell Lung Cancer (NSCLC) INDICATION: Treatment of malignancy associated weight loss or anorexia in patients with NSCLC. STUDY DRUG: Anamorelin...

Neoadjuvant Chemohormonal Therapy With Radical Prostatectomy for Localized Prostate Cancer
Post

Neoadjuvant Chemohormonal Therapy With Radical Prostatectomy for Localized Prostate Cancer

By: Melissa Steele-OgusPosted: Thursday, December 10, 2020 Although radical prostatectomy remains one of the primary treatments of localized high-risk prostate cancer, biochemical progression-free survival remains lower than ideal. A study published in the Journal of Clinical Oncology compared the efficacy of radical prostatectomy versus chemohormonal therapy with androgen-deprivation therapy (ADT) plus docetaxel prior to radical prostatectomy. The...

Margetuximab-cmkb in Combination With Chemotherapy Approved by FDA for Metastatic Breast Cancer
Post

Margetuximab-cmkb in Combination With Chemotherapy Approved by FDA for Metastatic Breast Cancer

By: JNCCN 360 StaffPosted: Friday, December 18, 2020 The U.S. Food and Drug Administration (FDA) recently approved the HER2-targeted monoclonal antibody margetuximab-cmkb (Margenza) in combination with chemotherapy for the treatment of adults with metastatic HER2-positive breast cancer who have received at least two prior anti-HER2 regimens (one of which was for metastatic disease), according to...